市場調查報告書
商品編碼
1451546
兒科疫苗市場報告(按類型(多價、單價)、技術(結合疫苗、減毒活疫苗、去活化疫苗、亞基疫苗、類毒素等)、應用(傳染病、癌症、過敏等)和地區2024 -2032Pediatric Vaccines Market Report by Type (Multivalent, Monovalent), Technology (Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid, and Others), Application (Infectious Disease, Cancer, Allergy, and Others), and Region 2024-2032 |
2023年全球兒科疫苗市場規模達370億美元。展望未來, IMARC Group預計到2032年市場規模將達到703億美元,2024-2032年複合年成長率(CAGR)為7.26%。疫苗接種計劃的不斷開展、對組合疫苗的日益關注以及製藥公司和醫療保健組織之間為快速開發和分配疫苗而加強的合作夥伴關係是推動市場的一些主要因素。
兒科疫苗是一種刺激免疫系統辨識和對抗特定傳染源(例如細菌或病毒)的醫療製劑。它們包含弱化或去活化形式的病原體或病原體的成分,促使免疫系統針對目標疾病形成防禦機制。它們可以預防麻疹、小兒麻痺、百日咳、肝炎和流感。它們在被批准使用之前經過嚴格的測試和評估,以確保其安全性。它們可以防止可能導致兒童嚴重併發症或死亡的疾病傳播。
目前,兒童脊髓灰質炎、結核病和瘧疾等各種傳染病和可能危及生命的疾病的日益增多正在推動市場的成長。除此之外,世界各地政府不斷採取的旨在讓兒童免疫預防可預防疾病的措施也促進了市場的成長。此外,疫苗儲存和分配方法的技術不斷進步,以改善醫療基礎設施低度開發地區的供應鏈,這提供了良好的市場前景。除此之外,製藥公司和醫療保健組織之間為快速開發和分銷疫苗而加強的合作夥伴關係正在支持市場的成長。此外,世界各地為改善醫療保健服務而不斷建設的診所和醫院也促進了市場的成長。
加強疫苗接種計畫的實施
疫苗接種計劃的持續實施顯著提振了兒科疫苗市場。這些疫苗接種措施得到了政府和非政府組織的支持,在保障兒童的健康和福祉方面發揮關鍵作用。隨著越來越多的兒童接受各種疾病的基本免疫接種,對兒科疫苗的需求也成比例增加。除此之外,以疾病預防為重點的疫苗接種計畫正在減少兒童特定疾病的發生率。這隨後會減輕醫療保健系統和家庭的負擔,從而提高兒童及其照顧者的整體生活品質。此外,家長和醫療保健提供者對免疫接種重要性的認知不斷提高,疫苗接種率也隨之提高。
越來越關注組合疫苗
對組合疫苗的高度重視有助於兒科疫苗市場的積極發展。聯合疫苗透過單一配方提供對多種疾病的保護,從而提供了一種策略性的免疫方法。這種方法簡化了醫療保健提供者、護理人員和兒童等的疫苗接種過程,從而提高了依從性和疫苗覆蓋率。此外,聯合疫苗解決了疫苗猶豫和漏服可能性的挑戰。由於兒童透過一次注射即可獲得多種疾病的保護,因此疫苗接種的負擔顯著減輕。這鼓勵家長遵守建議的疫苗接種計劃,並有助於實現更高的全面免疫覆蓋率。
新型疫苗的不斷開發
新型疫苗的持續發展在推動兒科疫苗市場的積極成長方面發揮關鍵作用。專門針對兒童健康需求量身訂製的新疫苗的出現有助於加強疾病預防、改善公共衛生結果並擴大市場機會。新型疫苗的開發也反映了疫苗技術和研究的進步。基因組學和生物資訊學等尖端研究方法使科學家能夠更快、更準確地識別潛在的候選疫苗。這種加快的發現速度正在創造出有效且符合不斷變化的流行病學情況的疫苗。此外,新型疫苗的持續發展正在刺激公共衛生組織、研究機構和疫苗製造商之間的合作。這些夥伴關係有助於及時推出新疫苗,並確保將其有效分發給兒科族群。
The global pediatric vaccines market size reached US$ 37.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 70.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.26% during 2024-2032. The growing conduction of vaccination programs, increasing focus on combination vaccines, and rising partnerships between pharmaceutical companies and healthcare organizations for fast-tracking the development and distribution of vaccines are some of the major factors propelling the market.
Pediatric vaccines are medical preparations that stimulate the immune system to recognize and fight specific infectious agents, such as bacteria or viruses. They comprise weakened or inactivated forms of the pathogens, or components of the pathogens, which prompt the immune system to develop a defense mechanism against the targeted disease. They provide protection from measles, polio, pertussis (whooping cough), hepatitis, and influenza. They undergo rigorous testing and evaluation to ensure their safety before being approved for use. They prevent the spread of diseases that can cause severe complications or death in children.
At present, the increasing occurrence of various infectious and potentially life-threatening diseases, such as polio, tuberculosis (TB), and malaria among children, is impelling the growth of the market. Besides this, rising government initiatives around the world aimed at immunizing children against preventable diseases are contributing to the growth of the market. In addition, the growing technological advancements in vaccine storage and distribution methods for improving the supply chain in regions where medical infrastructure may be less developed are offering a favorable market outlook. Apart from this, increasing partnerships between pharmaceutical companies and healthcare organizations for fast-tracking the development and distribution of vaccines are supporting the growth of the market. Additionally, the rising construction of clinics and hospitals around the world to improve healthcare services is bolstering the growth of the market.
Growing conduction of vaccination programs
The increasing implementation of vaccination programs is notably bolstering the pediatric vaccines market. These vaccination initiatives, supported by governmental and non-governmental organizations, play a pivotal role in safeguarding the health and well-being of children. As more children receive essential immunizations against various diseases, the demand for pediatric vaccines experiences a proportional rise. Besides this, vaccination programs, with their focus on disease prevention, are decreasing the incidence of targeted illnesses among children. This subsequently translates into a reduced burden on healthcare systems and families, thereby enhancing the overall quality of life for children and their caregivers. Furthermore, the growing awareness among parents and healthcare providers about the importance of immunizations is rising the vaccine uptake rates.
Increasing focus on combination vaccines
The heightened emphasis on combination vaccines is contributing to the positive evolution of the pediatric vaccines market. Combination vaccines offer a strategic approach to immunization by providing protection against multiple diseases in a single formulation. This approach simplifies the vaccination process for healthcare providers, caregivers, and children alike, resulting in improved compliance and vaccine coverage rates. Moreover, combination vaccines address the challenges of vaccine hesitancy and the possibility of missed doses. As children receive protection against multiple diseases with one injection, the perceived burden of vaccinations is significantly reduced. This encourages parents to adhere to recommended vaccination schedules and contributes to achieving higher rates of full immunization coverage.
Rising development of novel vaccines
The increasing development of novel vaccines is playing a pivotal role in driving positive growth within the pediatric vaccines market. The emergence of new vaccines tailored specifically for the health needs of children contributes to enhanced disease prevention, improved public health outcomes, and expanded market opportunities. The development of novel vaccines also reflects advancements in vaccine technology and research. Cutting-edge research methodologies, such as genomics and bioinformatics, enable scientists to identify potential vaccine candidates more rapidly and accurately. This accelerated pace of discovery is creating vaccines that are efficacious and align with the evolving epidemiological landscape. Furthermore, the rising development of novel vaccines is stimulating collaboration between public health organizations, research institutions, and vaccine manufacturers. These partnerships facilitate the timely introduction of new vaccines and ensure their efficient distribution to the pediatric population.
IMARC Group provides an analysis of the key trends in each segment of the global pediatric vaccines market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, technology, and application.
Multivalent
Monovalent
Multivalent dominates the market
The report has provided a detailed breakup and analysis of the market based on the type. This includes multivalent and monovalent. According to the report, multivalent represented the largest segment.
Multivalent pediatric vaccines refer to immunization formulations that provide protection against multiple diseases through a single vaccine injection. These vaccines are designed to target two or more different disease-causing agents, such as viruses or bacteria, in a single formulation. Multivalent pediatric vaccines streamline the vaccination process by offering protection against multiple diseases with a single injection. This eliminates the need for multiple shots, reducing discomfort for children and simplifying the vaccination schedule for healthcare providers and caregivers. Multivalent pediatric vaccines optimize healthcare resources by combining multiple vaccines into a single formulation. This can result in cost savings for healthcare systems and reduce the logistical challenges associated with administering separate vaccines.
Conjugate
Live Attenuated
Inactivated
Subunit
Toxoid
Others
Conjugate holds the largest share in the market
A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes conjugate, live attenuated, inactivated, subunit, toxoid, and others. According to the report, conjugate accounted for the largest market share.
Conjugate vaccines are a type of immunization that enhances the immune response against certain bacteria that have a protective polysaccharide outer coating. These vaccines work by linking or conjugating the bacterial polysaccharides to a carrier protein, creating a complex that stimulates a stronger and more effective immune response, especially in young children whose immune systems might not respond well to polysaccharides alone. Conjugate vaccines not only protect vaccinated individuals but can also reduce the carriage of bacteria in the population. This indirectly limits the spread of bacteria among both vaccinated and unvaccinated individuals. Conjugate vaccines contribute to herd immunity, which is essential for the prevention of the spreading of various infectious diseases among unvaccinated individuals.
Infectious Disease
Cancer
Allergy
Others
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes infectious disease, cancer, allergy, and others.
Pediatric vaccines play a crucial role in preventing infectious diseases among children. By providing immunity against harmful pathogens, vaccines contribute to the health and well-being of children and infants. These vaccines are carefully developed based on scientific examination and clinical trials to ensure their safety and effectiveness.
Pediatric vaccines for cancer aim to prevent certain types of cancers that primarily affect children. They target certain infections, such as human papillomavirus (HPV) and hepatitis B virus (HBV) and are known to increase the risk of developing cancer. Besides this, administering vaccines during childhood allows for early prevention of cancer-related infections. This early intervention aligns with a proactive health approach, reducing the risk of cancer development later in life.
Pediatric vaccines play a crucial role in preventing a range of allergies among children. By bolstering the response of the immune system, vaccines help mitigate the risk of developing allergies to common allergens like pollen, dust, and pet dander.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest pediatric vaccines market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region due to the rising investment in research operations for the development of various novel vaccines for the prevention of infectious and chronic diseases. Besides this, the increasing awareness among parents and caregivers about the importance of immunization is propelling the growth of the market. Apart from this, rising improvements in the healthcare infrastructure to provide quality treatment and other healthcare facilities to individuals are supporting the growth of the market.
Asia Pacific is estimated to expand further in this domain due to the increasing occurrence of infectious diseases caused by various novel viruses. Besides this, rising initiatives taken by governing agencies and regulatory bodies to promote the significance of vaccination in children are bolstering the growth of the market.
Key market players are diligently focused on enhancing their business strategies by consistently investing in research operations to formulate innovative vaccines that cater to evolving healthcare needs. They are fostering collaborations with research institutions and regulatory bodies to ensure the safety and efficacy of their products. Leading companies are strengthening their supply chain management and distribution networks to ensure timely availability of vaccines. Furthermore, top industry players are actively engaging in educational initiatives to increase awareness about the importance of vaccination, fostering trust and credibility within the community. This concerted effort to innovate, collaborate, and educate showcases their commitment to advancing the field of pediatric vaccines and contributing to public health on a global scale.
Abbott Laboratories
Bio-Med Private Limited
Daiichi Sankyo Company Limited
GSK plc
Indian Immunologicals Limited (National Dairy Development Board)
Merck & Co. Inc.
Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
Panacea Biotec Limited
Pfizer Inc.
Sanofi S.A.
Sinovac Biotech Ltd.